Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP001265

Drug Information
SynonymsAbbott Brand of Trimethadione; Trimethdione; Trimetadione [DCIT]; SPBio_002390; D00392; Petilep; Trimethadione [INN:JAN]; Tridilona; BPBio1_000517; Tioxanona; Tridione (TN); InChI=1/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3; CHEBI:131804; Epidione; T0781_SIGMA; NSC 15799; C6H9NO3; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; Convexina; Pitmal; Tridone; AC1L1KNK; Minoaleuiatin; Trioxanona; NSC15799; NCGC00016383-01; Prestwick1_000515; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; CHEMBL695; Trimethinum; Trimetin; Trimethin; Prestwick2_000515; ZINC01530710; EINECS 204-845-8; Trimedal; Absentol; IRYJRGCIQBGHIV-UHFFFAOYSA-; Epidone; Convenixa; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]; Triozanona; UNII-R7GV3H6FQ4; Prestwick_815; trimethadione; Epixal; AC1Q3XZF; D014293; Trimethadion; Absetil; BRN 0121627; SMR000499583; Prestwick0_000515; Trimethadione (JP15/INN); Edion; Trimedone; HMS1569H11; Mino-Aleviatin; Tromedone; Petidon; T0781_FLUKA; Trimetadione; Neo-Absentol; CID5576; Prestwick3_000515; CAS-127-48-0; Tredione; Minoaleviatin; Trimetadiona; 3,5,5-Trimethyl-2,4-oxazolidinedione; WLN: T5OVNV EHJ C1 E1 E1; HMS2093D10; 3,5,5,-Trimethyloxazolidine-2,4-dione; Trimethadionum [INN-Latin]; MolPort-001-846-840; BSPBio_000469; A 2297; Troxidone; 127-48-0; Trimethadionum; 3,5,5-Trojmetylooksazolidyno-2,4-dion; Tridion; Trioksal; Tridione; NCGC00016383-02; LS-7736; MLS001076685; Etydion; Ptimal; Trilidona; 3,3,5-Trimethyl-2,4-diketooxazolidine; 2,4-OXAZOLIDINEDIONE, 3,5,5-TRIMETHYL-; Trimetadiona [INN-Spanish]; Petimalin; DB00347; Tricione; Petidion; NSC169503    
IndicationEpileptic conditionsApproved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAnticonvulsants    
CAS NumberCAS 127-48-0
PubChem Compound IDCID 5576.    
PubChem Substance IDSID 79578.    
SuperDrug ATC IDN03AC02;    
SuperDrug CAS ID000127480;    
TargetVoltage-dependent T-type calcium channelBlocker[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 005856 To Reference
Ref 2Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60. Epub 2006 Dec 31. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543